RAPS: Federal Circuit: Use of a CMO Prior to Filing Drug Patents Does Not Invalidate the Patents

Pharmaceutical and biotech companies will likely be relieved to hear that the use of a contract manufacturing organization (CMO) cannot cause a drug’s patents to be invalidated under what’s known as the “on sale” bar, according to an opinion released Monday from the US Court of Appeals for the Federal Circuit.